kalsiumfolinat pfizer 10 mg/ ml
pfizer as - kalsiumfolinat - injeksjonsvæske, oppløsning - 10 mg/ ml
calciumfolinate teva 15 mg
teva sweden ab - kalsiumfolinat - tablett - 15 mg
calciumfolinate teva 10 mg/ ml
teva sweden ab - kalsiumfolinat - injeksjonsvæske, oppløsning - 10 mg/ ml
nuvaxovid
novavax cz, a.s. - sars cov-2 (original) recombinant spike protein, sars-cov-2 (omicron xbb.1.5) recombinant spike protein - covid-19 virus infection - covid-19 vaccines - nuvaxovid is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. bruk av denne vaksinen skal være i samsvar med offisielle anbefalinger. nuvaxovid xbb. 5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. bruk av denne vaksinen skal være i samsvar med offisielle anbefalinger.
fluorouracil accord 50 mg/ ml
accord healthcare b.v. - fluorouracilnatrium - injeksjons-/infusjonsvæske, oppløsning - 50 mg/ ml
methotrexate pfizer 25 mg/ ml
pfizer as - metotreksat - injeksjons-/infusjonsvæske, oppløsning - 25 mg/ ml
methotrexate rivopharm 100 mg/ ml
rivopharm ltd. - metotreksat - konsentrat til infusjonsvæske - 100 mg/ ml
suivac app vet.
chemvet dk a/s - actinobacillus pleuropneumoniae serovar 2, inaktivert / actinobacillus pleuropneumoniae serovar 9, inaktivert / toksoid apx i / toksoid apx ii / toksoid apx iii - injeksjonsvæske, emulsjon
shingrix
glaxosmithkline biologicals sa - recombinant varicella zoster virus glycoprotein e - herpes zoster - vaksiner - shingrix is indicated for prevention of herpes zoster (hz) and post-herpetic neuralgia (phn), in:adults 50 years of age or older;adults 18 years of age or older at increased risk of hz. bruk av shingrix skal være i samsvar med offisielle anbefalinger.
arexvy
glaxosmithkline biologicals s.a. - respiratory syncytial virus recombinant glycoprotein f stabilised in the pre-fusion conformation (rsvpref3) produced in chinese hamster ovary (cho) cells by recombinant dna technology - respiratorisk syncytialvirusinfeksjoner - vaksiner - arexvy is indicated for active immunisation for the prevention of lower respiratory tract disease (lrtd) caused by respiratory syncytial virus in adults 60 years of age and older. bruk av denne vaksinen skal være i samsvar med offisielle anbefalinger.